Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case–Control Study

References

• Miller KD, Fidler‐Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL. Cancer statistics for adolescents and young adults, 2020. CA: A Cancer Journal for Clinicians. 2020;70(6):443–459. doi:10.3322/caac.21637
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Gambardella C, Patrone R, Di Capua F, et al. The role of prophylactic central compartment lymph node dissection in elderly patients with differentiated thyroid cancer: a multicentric study. BMC Surg. 2019;1:18.
   Google Scholar
• Liu H, Yang D, Li L, Tu Y, Chen C, Sun S. Appraisal of radioiodine refractory thyroid cancer: advances and challenges. Am J Cancer Res. 2020;10(7):1923–1936.
   PubMed Web of Science ®Google Scholar
• Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017;317(13):1338–1348.
   PubMed Web of Science ®Google Scholar
• Shobab L, Gomes-Lima C, Zeymo A, et al. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Thyroid. 2019;29(9):1262–1268.
   PubMed Web of Science ®Google Scholar
• Gao L, Lin Y, Jiang Y, et al. Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer. Medicine. 2019;98(45):e17876.
   PubMed Web of Science ®Google Scholar
• Yang X, Li J, Li X, et al. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. J Nucl Med. 2017;58(2):258–265.
   PubMed Web of Science ®Google Scholar
• Salvatori M, Biondi B, Rufini V. 2- F-18 -fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol. 2015;173(3):R115–R130.
   PubMed Web of Science ®Google Scholar
• Choi SE, Pyo JY, Kim JS, Shin E, Hong SW. Molecular and Histopathologic Characteristics of Radioiodine-Refractory Papillary Thyroid Cancer. Lab Investigation. 2016;96:147A–148A.
   Web of Science ®Google Scholar
• Liu J, Liu R, Shen X, Zhu G, Li B, Xing M. The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. J Nucl Med. 2020;61(2):177–182. doi:10.2967/jnumed.119.227652
   PubMed Web of Science ®Google Scholar
• Colombo C, Minna E, Gargiuli C, et al. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer. J Exp Clin Cancer Res. 2020;39(1):245. doi:10.1186/s13046-020-01757-x
   PubMed Web of Science ®Google Scholar
• Collina F, La Sala L, Liotti F, et al. AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer. Cancers. 2019;11(6):785. doi:10.3390/cancers11060785
   PubMed Web of Science ®Google Scholar
• Jung CK, Jung S-H, Jeon S, et al. Risk Stratification Using a Novel Genetic Classifier Including PLEKHS1 Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis. Thyroid. 2020;30(11):1589–1600. doi:10.1089/thy.2019.0459
   PubMed Web of Science ®Google Scholar
• Luo Y, Jiang H, Xu W, et al. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: a Systematic Review and Meta-Analysis. Front Oncol. 2020;10:549882. doi:10.3389/fonc.2020.549882
   PubMed Web of Science ®Google Scholar
• de la Fouchardiere C, Decaussin-Petrucci M, Berthiller J, et al. Predictive factors of outcome in poorly differentiated thyroid carcinomas. Eur J Cancer. 2018;92:40–47.
   PubMed Web of Science ®Google Scholar
• Laisupasin P, Thompat W, Sukarayodhin S, Sornprom A, Sudjaroen Y. Comparison of Serum Lipid Profiles between Normal Controls and Breast Cancer Patients. J Lab Physicians. 2013;5(1):38–41.
   PubMedGoogle Scholar
• Acharya S, Rail P, Hallikeri K, Anehosur V, Kale J. Serum lipid profile in oral squamous cell carcinoma: alterations and association with some clinicopathological parameters and tobacco use. Int J Oral Maxillofac Surg. 2016;45(6):713–720.
   PubMed Web of Science ®Google Scholar
• Shen JG, Jin LD, Dong MJ, Wang LB, Zhao WH, Shen J. Low level of serum high-density lipoprotein cholesterol in gastric cancer correlates with cancer progression but not survival. Transl Cancer Res. 2020;9(10):6206–6213.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu B, Zeng Y, Shen H, Zhang J, Wang X. Clinical lipidomics in understanding of lung cancer: opportunity and challenge. Cancer Lett. 2020;470:75–83.
   PubMed Web of Science ®Google Scholar
• Li D, Zhou L, Ma C, et al. Comparative analysis of the serum proteome profiles of thyroid cancer: an initial focus on the lipid profile. Oncol Lett. 2019;18(3):3349–3357.
   PubMed Web of Science ®Google Scholar
• Ozmen S, Timur O, Calik I, et al. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer. Endocr Regul. 2017;51(3):131–136.
   PubMedGoogle Scholar
• Feng J, Wang Y, Shan G, Gao L. Clinical and prognostic value of neutrophil-lymphocyte ratio for patients with thyroid cancer A meta-analysis. Medicine. 2020;99(20):e19686.
   PubMed Web of Science ®Google Scholar
• Ordookhani A, Motazedi A, Burman KD. Thrombosis in Thyroid Cancer. Int J Endocrinol Metab. 2018;16(1):e57897.
   PubMed Web of Science ®Google Scholar
• Takata N, Miyagawa M, Matsuda T, et al. Usefulness of albumin-globulin ratio as a clinical prognostic factor in patients with thyroid cancer treated with radioiodine. Ann Nucl Med. 2021;35(9):1015–1021.
   PubMed Web of Science ®Google Scholar
• Wassermann J, Bernier M-O, Spano J-P, et al. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. Oncologist. 2016;21(1):50–58.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang X, Li H, Li X, Lin Y. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis. PLoS One. 2017;12(7):e0179664.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surgery. 2014;12(12):1495–1499.
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki [homepage on the Internet]; 2016. Available from: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/. Accessed October 15, 2022.
   Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Perrier ND, Brierley JD, Tuttle RM. Differentiated and Anaplastic Thyroid Carcinoma: major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. Cancer J Clin. 2018;68(1):56–63.
   Web of Science ®Google Scholar
• Shen W, Song Z, Zhong X, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1(3):e36.
   Google Scholar
• Wu DY, Qiao D, Zhang X, et al. Lipid profiles as potential mediators linking body mass index to osteoporosis among Chinese adults: the Henan Rural Cohort Study. Osteoporosis Int. 2019;30(7):1413–1422.
   PubMed Web of Science ®Google Scholar
• Attard R, Dingli P, Doggen CJM, Cassar K, Farrugia R, Wettinger SB. The impact of frequency, pattern, intensity, and type of alcohol consumption, and its combined effect with smoking on inflammation, lipid profile, and the risk of myocardial infarction. J Public Health Heidelberg. 2021;29(3):611–624.
   Web of Science ®Google Scholar
• Kaneva AM, Bojko ER. Sex differences in the association between obesity and hypertension. Arch Physiol Biochem. 2021;1:548.
   Google Scholar
• Shihab AS, Hamdi MA, Jumaa AM, Marbut MM, Jwad SK. Dyslipidemia and other parameters in women with pregnancy induced hypertension. J Population Therapeutics Clin Pharmacol. 2022;29(1):116–121.
   Web of Science ®Google Scholar
• Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6(6):1353–1363.
   PubMed Web of Science ®Google Scholar
• Fernandez LP. Alterations of Lipid Metabolism in Cancer: implications in Prognosis and Treatment. Front Oncol. 2020;10:e19686.
   Web of Science ®Google Scholar
• Lu C-W, Lo Y-H, Chen C-H, et al. VLDL and LDL, but not HDL, promote breast cancer cell proliferation, metastasis and angiogenesis. Cancer Lett. 2017;388:130–138.
   PubMed Web of Science ®Google Scholar
• Sahin M, Ucan B, Ginis Z, et al. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients. Med Oncol. 2013;30(2):589.
   PubMed Web of Science ®Google Scholar
• Wei S, Yun X, Ruan X, Wei X, Zheng X, Gao M. Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles. Oncol Lett. 2019;18(6):6670–6678.
   PubMed Web of Science ®Google Scholar
• Zhou X, Xia E, Bhandari A, et al. LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer. Biochem Biophys Res Commun. 2018;503(1):257–263.
   PubMed Web of Science ®Google Scholar
• Verma A, Qayyum R. Anion gap and cancer mortality: insight from NHANES database. J Clin Oncol. 2017;35:e13068.
   Web of Science ®Google Scholar
• Turcotte A, Achi S, Mamlouk O, Mandayam S. Electrolytes disturbances in cancer patients. Curr Opin Nephrol Hypertens. 2022;31(5):425–434.
   PubMed Web of Science ®Google Scholar
• Alsirafy SA, Sroor MY, Al-Shahri MZ. Predictive Impact of Electrolyte Abnormalities on the Admission Outcome and Survival of Palliative Care Cancer Referrals. J Palliat Med. 2009;12(2):177–180.
   PubMed Web of Science ®Google Scholar
• Kang Z, Jifu E, Yu E, Cai H. Correlation between neutrophils changes and prognosis of colorectal cancer. Chine J General Surgery. 2018;33(10):845–848.
   Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1):173.
   PubMed Web of Science ®Google Scholar
• Oberg -H-H, Wesch D, Kalyan S, Kabelitz D. Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells. Front Immunol. 2019;10:1690.
   PubMed Web of Science ®Google Scholar
• Manohar PM, Beesley LJ, Bellile EL, Worden FP, Avram AM. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med. 2018;43(9):641–647.
   PubMed Web of Science ®Google Scholar
• Cheng X, Xu S, Zhu Y, et al. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer. Eur J Clin Invest. 2022;52(4):e13721.
   PubMed Web of Science ®Google Scholar
• Marotta V, Sciammarella C, Chiofalo MG, et al. Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer. 2017;24(9):485–493.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Jia Q, Tan J, Meng Z. Serum biomarkers for thyroid cancer. Biomark Med. 2020;14(9):807–815.
   PubMed Web of Science ®Google Scholar
• Feldt-Rasmussen U, Verburg FA, Luster M, et al. Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma. Curr Med Chem. 2014;21(32):3687–3692.
   PubMed Web of Science ®Google Scholar
• Demir F, Hasbek Z, Erselcan T, Turgut B. The role of anti-thyroglobulin antibody in treatment and follow up of differentiated thyroid cancer. Ann Clin Analytical Med. 2020;11(3):207–210.
   Google Scholar
• Ge J, Wang J, Wang H, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J Cancer. 2020;11(4):932–939.
   PubMed Web of Science ®Google Scholar
• Verdickt S, Van Nes F, Moyson C, et al. TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for hypothyroidism in Graves’ disease. Eur Thyroid J. 2022;11(4):e220047.
   PubMed Web of Science ®Google Scholar
• Bastos AU, Oler G, Nakano Nozima BH, Moyses RA, Cerutti JM. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol. 2015;173(4):525–540.
   PubMed Web of Science ®Google Scholar
• Anekpuritanang T, Uataya M, Claimon A, Laokulrath N, Pongsapich W, Pithuksurachai P. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF(V600E) Mutation. Onco Targets Ther. 2021;14:3959–3969.
   PubMed Web of Science ®Google Scholar
• Sugino K, Nagahama M, Kitagawa W, et al. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr J. 2018;65(3):299–306.
   PubMed Web of Science ®Google Scholar
• Li G, Lei J, Song L, et al. Radioiodine refractoriness score: a multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas. Cancer Med. 2018;7(11):5448–5456.
   PubMed Web of Science ®Google Scholar